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The prognosis of patients infected with human immunodeficiency virus (HIV) type 1 has dramatically improved since the
advent of potent antiretroviral therapies (ARTs), which have enabled sustained suppression of HIV replication and recovery
of CD4 T cell counts. Knowledge of the function of CD4 T cells in immune reconstitution was derived from large clinical
studies demonstrating that primary and secondary prophylaxis against infectious agents, such as Pneumocystis jirovecii
(Pneumocystis carinii), Mycobacterium avium complex, cytomegalovirus, and other pathogens, can be discontinued safely
once CD4 T cell counts have increased beyond pathogen-specific threshold levels (usually 1200 CD4 T cells/mm3) for 3–6
months. The downside of immune reconstitution is an inflammatory syndrome occurring days to months after the start of
ART, with outcomes ranging from minimal morbidity to fatal progression. This syndrome can be elicited by infectious and
noninfectious antigens. Microbiologically, the possible pathogenic pathways involve recognition of antigens associated with
ongoing infection or recognition of persisting antigens associated with past (nonreplicating) infection. Specific antimicrobial
therapy, nonsteroidal anti-inflammatory drugs, and/or steroids for managing immune reconstitution syndrome should be
considered.
The hallmark of HIV disease is the continuous depletion of
CD4 T cells, leading to progressive immunodeficiency, oppor-
tunistic diseases, and death [1]. Despite the fact that CD4 T
cells function at a pathogen-specific level that is not yet as-
sessable in the clinical routine, a clear inverse relationship exists
between the number of CD4 T cells in the patient’s peripheral
blood and their risk of opportunistic infection. Thus, in asymp-
tomatic HIV-infected patients, total CD4 T cell counts provide
a major criterion for initiating primary prophylaxis against op-
portunist illness, such as Pneumocystis jirovecii (also known as
Pneumocystis carinii) pneumonia (if the CD4 T cell count is
!200 cells/mm3) and disseminated Mycobacterium avium com-
plex infection (if the CD4 T cell count is !50 cells/mm3) [2].
Conversely, an increase in CD4 T cell count after the sup-
pression of HIV replication by antiretroviral therapy (ART)
correlates with improved T cell responses to antigens and mi-
togens [3, 4] and adequate protection against specific oppor-
tunistic infections, allowing discontinuation of primary and
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secondary prophylaxis in clinical practice [5–9]. Thus, plasma
HIV load and peripheral CD4 T cell count represent surrogate
markers for assessing the risk of AIDS, as well as the need for
ART and/or prophylaxis [7, 10].
RECOVERY OF CD4 T CELL COUNTS
Recent studies indicate that CD4 T cell recovery is sustained
for 3–4 years in individuals with advanced HIV-1 infection
who receive ART [11, 12]. After an initial rapid increase in
CD4 T lymphocyte counts within the first 3–6 months of ART,
a second phase of slower increase occurs in most patients [13].
However, considerable individual variation has been noted in
this response. In fact, CD4 T cell counts may remain below
the critical threshold of 200 cells/mm3 in 10%–20% of treated
individuals [12]. Several factors are associated with impaired
CD4 T cell reconstitution, including older age, nonsuppressed
HIV replication, and treatment interruption [7, 12]. In general,
the lower the CD4 T cell count at the initiation of ART, the
longer it takes to reach desired target levels [14, 15]. Certain
investigations even suggest that CD4 T cell recovery may level
off before the physiological range is reached, particularly in
individuals who begin ART when their CD4 T cell counts are
extremely low (i.e., !50 cells/mm3) [15, 16]. Conversely, early
initiation of ART during primary HIV-1 infection may not only
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preserve but also rapidly restore memory and naive CD4 T
cells, which are crucial for the rate and the range of the adaptive
immune response [15]. These observations should be taken
into account when counseling the patient with respect to the
start of ART [17–19].
RECOVERY OF PATHOGEN-SPECIFIC
CD4 T CELL FUNCTION
In the late 1990s, it became evident that ART resulted not only
in a numerical increase in CD4 T cells, but also in a functional
immune reconstitution [3, 4]. Qualitative and quantitative re-
covery of pathogen-specific cellular and humoral responses has
been demonstrated for a number of agents, including myco-
bacteria, cytomegalovirus, Epstein-Barr virus, hepatitis B virus
(HBV) and hepatitis C virus (HCV), and Candida albicans [3,
20–22]. Improvements in pathogen-specific immune responses
to HBV and HCV are illustrated by seroconversion to anti-
HCV–positive or anti-Hbe–positive states and by clearance of
hepatitis [23–25]. With the possible exception of delayed-type
hypersensitivity skin testing for particular antigens, the more
sophisticated assays that measure cytokine concentration, lym-
phoproliferation, specific T cell receptors, or cytotoxicity have
not yet entered clinical routine and/or are lacking clinical val-
idation. In the clinical arena, randomized, open clinical studies,
as well as prospective cohorts, have demonstrated that stopping
primary prophylaxis for P. jirovecii is safe in patients with CD4
T cell counts that are stably reconstituted to 1200 cells/mm3
for 16 months [9, 26–31]. This same conclusion was reached
for M. avium complex in patients with CD4 T cell counts of
1100 cells/mm3 for 13 months, according to 2 randomized,
blinded trials and a cohort study in which disease occurred in
only 2 of 863 patients during a follow-up period of 1 year
[32–34].
Immunologically and clinically more challenging is the dis-
continuation of secondary prophylaxis, particularly when it
concerns pathogens with a propensity for latent infection in
vulnerable sites (e.g., cytomegalovirus or Toxoplasma gondii,
which have a propensity for latent infection in the CNS). For
P. jirovecii, Lopez et al. [30] demonstrated in a prospective trial
involving 113 individuals with a median follow-up period of
12 months that interruption of secondary prophylaxis is safe.
No case of P. jirovecii pneumonia was observed among the 60
patients who had CD4 T cell counts of 1200 cells/mm3 for 13
months and virus loads of !5000 copies/mL (no incidents per
100 person-years; 95% CI, 0–4.57 ) [30]. Similar results were
obtained from a large observational study [35] that analyzed
the data of 8 European HIV databases (no incidents per 100
person-years; 95% CI, 0–1.3). For Cryptococcus neoformans, a
prospective randomized trial confirmed that discontinuation of
secondary prophylaxis after adequate treatment for cryptococ-
cal meningitis is safe in patients who had CD4 T cell counts
of 1100 cells/mm3 and HIV loads of !50 copies/mL for 13
months [36].
For cytomegalovirus retinitis, observational studies and case
series indicate that secondary prophylaxis can be safely discon-
tinued provided that the disease is determined to no longer be
active by repeated ophthalmologic examination and a sustained
CD4 T cell increase to levels ranging from 1100 cells/mm3 to
1150 cells/mm3 for 16 months has been documented [37–43].
In these studies, the inclusion criteria regarding CD4 T cell
thresholds and/or increases varied considerably, from 50–150
cells/mm3, with nadirs ranging from 10–42 cells/mm3. However,
there were only 2 cases of cytomegalovirus disease among 1200
patients studied [37–43]. In the comprehensive study by Kirk et
al. [43], interruption of maintenance therapy against previous
infection with 4 common HIV-associated opportunistic patho-
gens was investigated. In this observational study, 358 patients
who were receiving ART and who had CD4 T cell counts of 150
cells/mm3 interrupted secondary prophylaxis. A total of 379 ep-
isodes were analyzed (162 episodes of cytomegalovirus disease,
103 episodes of M. avium complex infection, 75 episodes of
toxoplasmosis, and 39 episodes of cryptococcosis). Only 5 pa-
tients experienced a relapse during 781 person-years of follow-
up; 2 patients had cytomegalovirus disease, 2 patients had M.
avium complex infection, and 1 patient had toxoplasmosis [43].
Few of these events occurred at CD4 T cell counts greater than
the respective thresholds. The overall incidence of recurrent dis-
ease was calculated per 100 person-years as follows: cytomega-
lovirus, 0.54 (95% CI, 0.07–1.95); M. avium complex, 0.90 (95%
CI, 0.11–3.25); toxoplasmosis, 0.84 (95% CI, 0.02–4.68); and
cryptococcosis, 0.0 (95% CI, 0.00–5.27) [43]. Discontinuation
of antifungal therapy for disseminated histoplasmosis after ART
was investigated in 32 patients with CD4 T cell counts of 1150
cells/mm3 (median CD4 T cell count, 289 cells/mm3). No relapse
of disseminated histoplasmosis was observed (95% CI, 4.6 in-
cidents per 100 person years) [44], indicating that discontinu-
ation of antifungal treatment for disseminated histoplasmosis is
safe in this setting. In summary, the current recommendations
for discontinuing secondary prophylaxis require completion of
initial therapy, inactive disease, and stable CD4 T cell counts
greater than pathogen-related thresholds. For patients with P.
jirovecii infection and toxoplasmosis, a CD4 T cell count of 1200
cells/mm3 for 3 months is recommended; for patients with M.
avium complex infection, cytomegalovirus disease, and crypto-
coccosis, a CD4 T cell count of 1100 cells/mm3 for 6 months
is recommended (guidelines are available at http://
www.aidsinfo.nih.gov/guidelines/). However, CD4 T cell counts
have to be monitored so that prophylaxis can be reinitiated if
decreasing values are noted. Although there are no data specif-
ically addressing this issue, reinitiation of prophylaxis uses the
same thresholds as primary prophylaxis. As a note of caution,
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Table 1. Review of immune reconstitution syndrome, by pathogen.
Pathogen Manifestation Management Reference(s)
Mycobacterium avium complex Skin, focal lymphadenitis, pulmonary infiltrates, mediastinitis, liver
granuloma, osteomyelitis, cerebritis
Continue ART; antibiotics (steroids) [52–60]
Mycobacterium tuberculosis Pneumonitis, adult respiratory distress syndrome, lymphadenitis,
hepatitis, CNS tuberculosis, gut perforation, renal failure,
epididymitis
Continue ART; antibiotics (steroids) [61–66, 103–106]
Mycobacterium leprae Cutaneous lesions Continue ART; dapsone [67]
Cryptococcus species Meningitis, palsy, hearing loss, abscess, mediastinitis,
lymphadenitis
Continue ART; steroids; antifungals [68–73]
Pneumocystis jirovecii Pneumonitis Continue ART; steroids; antibiotics [74, 75]
Histoplasma species Lymph node granuloma Continue ART; antifungals [46]
Hepatitis B and C viruses Hepatitis Continue or discontinue ART; IFNa [20]
JC virus Contrast-enhanced CNS lesions, inflammatory infiltrates on biopsy Continue ART; steroids; cidofovira [76–78]
BK virus Hemorrhagic cystitis Continue ART; symptomatic
therapy
[50, 51, 79]
Herpes simplex virus Chronic erosive ulcera, encephalomyelits Continue ART; antiviralsa; steroidsa [80]
Varicella-zoster virus Zoster flares, sine herpete flares Continue ART; antivirals; steroidsa [81]
Cytomegalovirus Vitritis, cystoid macular edema, uveitis, vitreomacular traction Continue ART; IVIG; steroids;
vitrectomy; antivirals
[82]
Kaposi human herpes virus–8 Tracheal mucosal edema, obstruction Discontinue ART; clear airway;
steroids
[4]
Papillomavirus Inflamed warts, mollusca contagiosa Steroidsa; surgicala [83]
Parvovirus B19 Focal encephalitis IVIG; discontinue ART [76]
HIV Demyelinating leukoencephalopathy Steroidsa; discontinue ART [49]
Chlamydia trachomatis Reiter syndrome, urethritis, balanitis circinata, arthritis,
hemorrhagic conjunctivitis
Doxycyline [84]
Unknown Guillain-Barre´ syndrome Plasmapheresis; IVIG [85]
Unknown Sarcoidosis Steroidsa [86–89]
Unknown Appendicitis Surgical [90]
NOTE. ART, antiretroviral therapy; IVIG, intravenous immunoglobulin.
a Indicates uncertain benefit in some of the patients with the specified complication and may require individual decisions.
CD4 T cell thresholds are not absolute, but are only intended to
provide guidance. This is illustrated by data from the Swiss HIV
Cohort Study of patients with toxoplasmic encephalitis. Of these
patients, 7% were determined to have had CD4 T cell counts of
1200 cells/mm3 (which is the threshold recommended by the
Swiss guidelines), and 19.4% were determined to have had CD4
T cell counts of 1100 cells/mm3 (which is the threshold rec-
ommended by the US guidelines) [45].
IMMUNE RECONSTITUTION SYNDROME (IRS)
IRS is recognized as a potential complication that can occur
after potent ART [46]. The frequency of IRS has not been
reported conclusively, but it may be estimated to occur in 10%–
25% of patients who receive ART [47]. However, the first cases
of M. avium–associated IRS were reported to have occurred
after administration of zidovudine monotherapy [48]. Myco-
bacterial antigens are frequently implicated in IRS, and together
they represent almost one-third of all reported cases [20]. Other
infectious agents that are frequently associated with IRS include
C. neoformans, cytomegalovirus, and HBV and HCV. More
recently, it has been proposed that HIV-mediated IRS mediates
a novel form of severe demyelinating leucoencephalopathy in
the CNS [49]. Also, a role for BK virus–targeted IRS might
account for cases of hemorrhagic cystitis, as discussed elsewhere
[50, 51]. Table 1 summarizes manifestations associated with
different microbes and the reported management of those
manifestations.
The onset of IRS is characterized by paradoxical worsening
of clinical or laboratory parameters despite “favorable” devel-
opment of the HIV surrogate markers [63]. In the affected
patients, CD4 T cell counts are often !50 cells/mm3 at the start
of ART and subsequently increase 12–4 fold during the 12
months after initiation of ART, and a significant decrease in
HIV load of 12 log10 copies/mL is often noted [4, 20]. However,
initial experience of IRS occurring after zidovudine mono-
therapy suggests that small breaks of HIV replication may al-
ready be sufficient for IRS to occur in response to some par-
ticular antigens [48]. The interval between the start of ART
and the onset of IRS is highly variable, ranging from !1 week
to several months, but the majority of events occur within the
first 8 weeks after ART initiation [4, 20, 47] and occur in
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Table 2. Recommended management of immune reconstitution syndrome.
Variable Management
Differential pathogenesis
Unmasking and/or recognition of ongoing infections Antimicrobial therapy
Reconstituting immune reaction to nonreplicating antigens No antimicrobial therapy
Differential diagnosis
Drug toxicity Stop and/or modify antiretroviral or antimicrobial therapy
Drug failure Restart and/or adapt antimicrobial treatment
Treatment NSAIDs, steroids (timing, dosing, duration),a intravenous
immunoglobulins,a thalidomidea
NOTE. NSAIDs, nonsteroidal anti-inflammatory drugs.
a Indicates uncertain benefit in some of the patients with the specified complication and may require individual decisions.
patients with low mean CD4 T cell counts [47]. In vitro char-
acterization suggested that reconstitution occurred earlier in
response to antigens of ubiquitous or abundant exposure, com-
pared with antigens of low exposure (such as tetanus toxoid),
and that earlier reconstitution correlated with an increase in
memory CD4 T cells [3, 91]. Of note, HIV-specific immunity
is not adequately reconstituted in most patients [92], a fact
underscored by recent reports of HIV superinfection [93–95].
IRS may arise in 2 different settings, depending on whether
ART was started in a patient treated for ongoing opportunistic
infection or in a clinically stable patient with or without re-
quiring primary prophylaxis. For patients with active infection
and antimicrobial treatment for P. jirovecii or Mycobacterium
tuberculosis, for example, some clinicians may choose to defer
ART by 1–3 weeks to avoid high pill counts, cumulating tox-
icity, and possibly IRS. If IRS occurs in such patients, the dif-
ferential diagnosis includes failure of the antimicrobial therapy;
manifestation of a new opportunistic infection; unmasking of
an ongoing, previously undiagnosed infection; or manifestation
of a diagnosed, ongoing infection in a previously unrecognized
site of involvement. Although discontinuing ART has to be
considered (table 1), most clinicians prefer to continue ART if
the CD4 T cell counts are !100 cells/mm3 or if IRS manifests
months after ART has been initiated. There are no clear guide-
lines on when to stop ART. As gathered from anecdotal reports,
ART is more readily discontinued if inflammatory responses
are considered life-threatening, the responses are not amenable
to steroids, and the pathogens involved are not controllable by
specific antimicrobial treatments (as exemplified by IRS in re-
sponse to parvovirus B19 or polyomavirus JC [78, 96]), or if
ART toxicity was the main differential diagnosis (e.g., as in
hepatitis).
An increase in transaminase levels after the initiation of ART
is observed in 1%–5% of patients and is associated with co-
infection with HBV and/or HCV [97–99]. A recent study of
915 adverse events that occurred among 755 patients who were
receiving ART identified severe hepatotoxicity in 26 (3.4%) of
the patients (incidence, 4.2 adverse events per 100 person-
years), with risk factors being injection drug use, chronic al-
cohol abuse, and chronic viral hepatitis (including HBV and
HCV, as confirmed by histology) [100]. The incidence of liver
failure was 1.1%. Liver failure was associated with a lower CD4
T cell count at baseline (median, 94 cells/mm3), compared with
the CD4 T cell count at baseline of the 19 patients without
liver failure (median, 260 cells/mm3), suggesting a role for IRS
[100]. Drug hepatotoxicity is associated with ART regimens
that contain nevirapine, efavirenz, didanosine, zalcitabine, ri-
tonavir, or saquinavir [97, 101]. However, discontinuation of
ART may be associated with rebounding HBV replication in
patients coinfected with HIV–HBV who are treated with la-
mivudine- or tenofovir-containing regimens. In these cases,
continuation of monotherapy with lamivudine or tenofovir
should be considered. On the other hand, persistent HBV rep-
lication and the emergence of lamivudine-resistant HBV has
been observed in ∼10% of patients after long-term ART with
regimens containing lamivudine [102].
Specific treatments may be required for unusual manifes-
tations of IRS (table 1), such as surgical intervention in a case
of bowel perforation due to M. tuberculosis–mediated IRS [65].
Acute renal failure has been observed in a case of M. tuber-
culosis–associated IRS in a patient whose renal function was
initially normal, but who had documented prior miliary spread
and who had urine cultures positive for M. tuberculosis [103].
The unmasking, as a result of IRS, of previously undiagnosed
ongoing infections, such as Cryptococcus-associated meningitis,
has been previously described [68]. In fact, IRS in response to
the simultaneous occurrence of 2 entities (i.e., cytomegalovirus
and Cryptococcus species) has been reported [104].
The management of symptoms, particularly through the use
of nonsteroidal anti-inflammatory drugs, has been recom-
mended. Immune modulation is warranted, but specific drugs
and protocols are lacking. Thalidomide, intravenous immu-
noglobulins, and steroids have been discussed [20]. Steroids
represent an important, although double-edged, measure in IRS
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treatment. Systemic steroids are often considered when inflam-
matory damage at the site of involvement severely impairs or-
gan function (e.g., eye, liver, brain, or lungs) and becomes life-
threatening. For progressive multifocal leucoencephalopathy
mediated by polyomavirus JC, transient improvement of the
patient’s condition on administration of steroids that then
showed lethal progression has been reported. The unfavorable
course may be the result of several factors, including the ad-
vanced stage of the disease, the patient’s inability to mount a
complete immune response, and the protracted administration
of steroids (which adversely affected immune effectors), in ad-
dition to the lack of effective pathogen-specific antivirals. How-
ever, judicious use of steroids and further immune reconsti-
tution by continued ART remain the only option [77, 105].
Regarding the management of IRS, the question of whether
IRS is elicited by active infection or by persisting antigens arises
(table 2). If active infection is suspected, antimicrobial therapy
is warranted, and modification of treatment should be consid-
ered in cases in which the patient is already receiving antimi-
crobials. On the other hand, reconstitution of immune reaction
to persisting antigens of microbes that no longer replicate may
make antimicrobial therapy unnecessary and may, in fact, add
to toxicity. In clinical practice, it may be impossible to dissect
these entities, and hands-on antimicrobial therapy may be ad-
ministered even if an ongoing infection was not proven and if
the differential diagnosis includes antimicrobial treatment fail-
ure [8].
CONCLUSIONS
Immune reconstitution, marked by an increase in CD4 T cell
count, is the most crucial process that takes place in a patient
after initiation of ART. Success of ART translates into a sus-
tained recovery of CD4 T cells, which is the primary surrogate
marker used in clinical praxis. Recommendations for discon-
tinuing prophylaxis involve well-defined CD4 T cell count
thresholds. Nevertheless, clinical judgment may require adap-
tation of these recommendations, particularly in the first phase
of immune recovery. Because IRS may be more frequent in
patients with advanced HIV disease who are initiating ART,
this complication of immune recovery may decrease in fre-
quency if ART is initiated in patients whose CD4 T cell counts
have not already decreased to !200 cells/mm3.
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